ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,258.61
0.00%
Dow Jones
44,860.31
0.28%
Gold vs US Dollar
2,647.58
0.58%
Brent Oil
72.605
0.21%
Bitcoin
93,502.74
1.66%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Celularity Inc (CELU)

  7. Celularity Inc (CELU) News

Celularity (CELU)

Celularity Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CELU
DateTimeSourceHeadlineSymbolCompany
20/11/202413:30GlobeNewswire Inc.Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificNASDAQ:CELUCelularity Inc
18/11/202413:30GlobeNewswire Inc.Celularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterNASDAQ:CELUCelularity Inc
07/11/202413:00GlobeNewswire Inc.Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 MillionNASDAQ:CELUCelularity Inc
23/10/202412:30GlobeNewswire Inc.Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelNASDAQ:CELUCelularity Inc
22/10/202412:30GlobeNewswire Inc.Celularity Provides Corporate UpdateNASDAQ:CELUCelularity Inc
18/10/202422:00GlobeNewswire Inc.Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an AppealNASDAQ:CELUCelularity Inc
16/10/202421:15GlobeNewswire Inc.Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.NASDAQ:CELUCelularity Inc
05/09/202420:05GlobeNewswire Inc.Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment ConferenceNASDAQ:CELUCelularity Inc
28/08/202421:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELUCelularity Inc
28/08/202420:45GlobeNewswire Inc.Celularity Appoints Richard J. Berman to its Board of DirectorsNASDAQ:CELUCelularity Inc
23/08/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELUCelularity Inc
23/08/202421:00GlobeNewswire Inc.Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNASDAQ:CELUCelularity Inc
16/08/202420:45Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:CELUCelularity Inc
05/08/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELUCelularity Inc
31/07/202412:30GlobeNewswire Inc.Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023NASDAQ:CELUCelularity Inc
30/07/202420:26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CELUCelularity Inc
03/06/202412:38GlobeNewswire Inc.Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CELUCelularity Inc
24/05/202421:15GlobeNewswire Inc.Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNASDAQ:CELUCelularity Inc
14/05/202413:15GlobeNewswire Inc.Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyNASDAQ:CELUCelularity Inc
22/04/202412:00GlobeNewswire Inc.Celularity Inc. to Host Investor and Analyst Research & Development DayNASDAQ:CELUCelularity Inc
19/04/202421:30GlobeNewswire Inc.Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingNASDAQ:CELUCelularity Inc
18/04/202420:30GlobeNewswire Inc.Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024NASDAQ:CELUCelularity Inc
15/04/202412:00GlobeNewswire Inc.Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsNASDAQ:CELUCelularity Inc
08/04/202413:00GlobeNewswire Inc.Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsNASDAQ:CELUCelularity Inc
26/03/202413:00GlobeNewswire Inc.Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LNASDAQ:CELUCelularity Inc
20/03/202413:15GlobeNewswire Inc.Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyNASDAQ:CELUCelularity Inc
14/03/202413:15GlobeNewswire Inc.Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitNASDAQ:CELUCelularity Inc
12/03/202413:20GlobeNewswire Inc.Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressNASDAQ:CELUCelularity Inc
07/03/202414:35GlobeNewswire Inc.Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsNASDAQ:CELUCelularity Inc
26/02/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CELUCelularity Inc
 Showing the most relevant articles for your search:NASDAQ:CELU

Your Recent History

COIN
DYXUSD
DYX Network
LSE
LTSV
Short Vol
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Gold Trader

    1 year 35%, 2 years 45% and *3 years 60%

    *Across 3 years £3655.44 only £1462.17